PortalPublikationenBevacizumab as a treatment option for choroidal neovasculari...

Bevacizumab as a treatment option for choroidal neovascularisation due to large optic nerve drusen in a 14-year-old girl

Standard

Bevacizumab as a treatment option for choroidal neovascularisation due to large optic nerve drusen in a 14-year-old girl. / Steinhorst, Nils Alexander; Spitzer, Martin; Skevas, Christos.

in: GMS Ophthalmol Cases, Jahrgang 10, 2020, S. Doc33.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Steinhorst, NA, Spitzer, M & Skevas, C 2020, 'Bevacizumab as a treatment option for choroidal neovascularisation due to large optic nerve drusen in a 14-year-old girl', GMS Ophthalmol Cases, Jg. 10, S. Doc33. https://doi.org/10.3205/oc000160

APA

Steinhorst, N. A., Spitzer, M., & Skevas, C. (2020). Bevacizumab as a treatment option for choroidal neovascularisation due to large optic nerve drusen in a 14-year-old girl. GMS Ophthalmol Cases, 10, Doc33. https://doi.org/10.3205/oc000160

Vancouver

Steinhorst NA, Spitzer M, Skevas C. Bevacizumab as a treatment option for choroidal neovascularisation due to large optic nerve drusen in a 14-year-old girl. GMS Ophthalmol Cases. 2020;10:Doc33. https://doi.org/10.3205/oc000160

Bibtex

@article{c4184442b89d453a9e959aa7493af127,
title = "Bevacizumab as a treatment option for choroidal neovascularisation due to large optic nerve drusen in a 14-year-old girl",
abstract = "Purpose: To report the effects of a single intravitreous injection of bevacizumab for the treatment of secondary choroideal neovascularisation due to large optic disc drusen. Methods: A 14-year-old female patient with painless loss of vision in one eye presented with unusually large optic disc drusen and juxtapapillary choroidal neovascularisation with subretinal hemorrhage. She was treated with a single intravitreous injection of bevacizumab. Results: Visual acuity increased from 20/100 to 20/25 within 4 weeks after injection and remained at this level during the 12-month follow-up period. Conclusions: Bevacizumab is a possible primary treatment option for secondary choroidal neovascularisation due to large optic disc drusen in children as an alternative to other more invasive or complex procedures.",
author = "Steinhorst, {Nils Alexander} and Martin Spitzer and Christos Skevas",
note = "Copyright {\textcopyright} 2020 Steinhorst et al.",
year = "2020",
doi = "10.3205/oc000160",
language = "English",
volume = "10",
pages = "Doc33",
journal = "GMS Ophthalmol Cases",
issn = "2193-1496",

}

RIS

TY - JOUR

T1 - Bevacizumab as a treatment option for choroidal neovascularisation due to large optic nerve drusen in a 14-year-old girl

AU - Steinhorst, Nils Alexander

AU - Spitzer, Martin

AU - Skevas, Christos

N1 - Copyright © 2020 Steinhorst et al.

PY - 2020

Y1 - 2020

N2 - Purpose: To report the effects of a single intravitreous injection of bevacizumab for the treatment of secondary choroideal neovascularisation due to large optic disc drusen. Methods: A 14-year-old female patient with painless loss of vision in one eye presented with unusually large optic disc drusen and juxtapapillary choroidal neovascularisation with subretinal hemorrhage. She was treated with a single intravitreous injection of bevacizumab. Results: Visual acuity increased from 20/100 to 20/25 within 4 weeks after injection and remained at this level during the 12-month follow-up period. Conclusions: Bevacizumab is a possible primary treatment option for secondary choroidal neovascularisation due to large optic disc drusen in children as an alternative to other more invasive or complex procedures.

AB - Purpose: To report the effects of a single intravitreous injection of bevacizumab for the treatment of secondary choroideal neovascularisation due to large optic disc drusen. Methods: A 14-year-old female patient with painless loss of vision in one eye presented with unusually large optic disc drusen and juxtapapillary choroidal neovascularisation with subretinal hemorrhage. She was treated with a single intravitreous injection of bevacizumab. Results: Visual acuity increased from 20/100 to 20/25 within 4 weeks after injection and remained at this level during the 12-month follow-up period. Conclusions: Bevacizumab is a possible primary treatment option for secondary choroidal neovascularisation due to large optic disc drusen in children as an alternative to other more invasive or complex procedures.

U2 - 10.3205/oc000160

DO - 10.3205/oc000160

M3 - SCORING: Journal article

C2 - 32884887

VL - 10

SP - Doc33

JO - GMS Ophthalmol Cases

JF - GMS Ophthalmol Cases

SN - 2193-1496

ER -